Gyre Therapeutics
GYRE
43 hedge funds and large institutions have $6.39M invested in Gyre Therapeutics in 2022 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 8 increasing their positions, 17 reducing their positions, and 10 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2.28% less ownership
Funds ownership: 6.39% → 4.11% (-2.3%)
16% less funds holding
Funds holding: 51 → 43 (-8)
53% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 17
54% less capital invested
Capital invested by funds: $13.7M → $6.39M (-$7.36M)
80% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$120K |
| 2 |
Bank of New York Mellon
New York
|
+$93.5K |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
+$14.7K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$8.34K |
| 5 |
SI
Stephens Inc
Little Rock,
Arkansas
|
+$5.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$1.58M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$469K |
| 3 |
Renaissance Technologies
New York
|
-$398K |
| 4 |
PVI
Pura Vida Investments
New York
|
-$326K |
| 5 |
Morgan Stanley
New York
|
-$298K |
GYRE Hedge Fund Activity: Q1 2022 in Review
43 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q1 2022, worth a combined $6.39M — down 54% from $13.7M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of GYRE and 2 opened new positions — a net loss of 8 holders — while 17 trimmed existing stakes and 8 added.
The largest buyer was Sabby Management, adding an estimated $120K. The largest seller was OrbiMed, exiting entirely with an estimated $1.58M sold.
- 43 institutional investors held Gyre Therapeutics (GYRE) as of Q1 2022, down from 51 in Q4 2021.
- Funds reported $6.39M of Gyre Therapeutics stock for Q1 2022, down 54% quarter-over-quarter.
- 2 funds opened new Gyre Therapeutics positions in Q1 2022 and 10 closed out, a net change of -8 holders.
- The largest Gyre Therapeutics buyer in Q1 2022 was Sabby Management, an estimated $120K added.
- The largest Gyre Therapeutics seller in Q1 2022 was OrbiMed, an estimated $1.58M sold.
Based on aggregated 13F filings for Q1 2022.